Promising nanotherapy in treating leishmaniasis
Carregando...
Data
2018-08-25
Autores
de Souza, Aline
Marins, Débora Soares Souza
Mathias, Samir Leite
Monteiro, Lis Marie
Yukuyama, Megumi Nishitani
Scarim, Cauê Benito [UNESP]
Löbenberg, Raimar
Bou-Chacra, Nádia Araci
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with this infection. Nevertheless, only a few effective drugs are available, and each has a particular disadvantage; toxicity and long-term regimens compromise most chemotherapeutic options, which decreases patient compliance and adherence to the treatment and consequently the emergence of drug-resistant strains. Nano drug delivery systems (NanoDDS) can direct antileishmanial drug substances for intracellular localization in macrophage-rich organs such as bone marrow, liver, and spleen. This strategy can improve the therapeutic efficacy and reduce the toxic effects of several antileishmanial drug substances. This review is an effort to comprehensively compile recent findings, with the aim of advancing understanding of the importance of nanotechnology for treating leishmaniases.
Descrição
Palavras-chave
Drug delivery systems, Drug targeting, Human leishmaniasis, Nanotechnology, Nanotherapeutics, Treatment
Como citar
International Journal of Pharmaceutics, v. 547, n. 1-2, p. 421-431, 2018.